If You Invested in Inozyme Pharma, Inc. (INZY)

Inozyme Pharma, Inc. (historically traded on Nasdaq under the symbol INZY) was a clinical-stage biopharmaceutical company focused on rare diseases that affect bone health and blood vessel function. According to company disclosures and transaction documents, Inozyme became a wholly owned subsidiary of BioMarin Pharmaceutical Inc. on July 1, 2025, following the completion of an all-cash acquisition. A Form 25 filed with the SEC on July 1, 2025, confirms the removal of Inozyme’s common stock from listing on the Nasdaq Stock Market, and a subsequent Form 15 filed on July 11, 2025, certifies the termination of registration of its common stock under the Securities Exchange Act of 1934. As a result, INZY is now a former Nasdaq-listed security and Inozyme operates within BioMarin’s corporate structure.

Before the acquisition, Inozyme described itself as a clinical-stage biopharmaceutical company dedicated to developing therapeutics that target the PPi-Adenosine Pathway, a key regulator of mineralization in bones and soft tissues and of blood vessel function. Company materials state that disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency and ABCC6 Deficiency, as well as conditions such as calciphylaxis and ossification of the posterior longitudinal ligament (OPLL). Inozyme’s work focused on the ENPP1 enzyme, which generates inorganic pyrophosphate (PPi), and adenosine, molecules that help regulate mineral deposition and intimal proliferation in blood vessels.

Inozyme’s lead investigational product candidate, INZ-701, is described in company communications as an ENPP1 Fc fusion protein enzyme replacement therapy (ERT). It is designed to increase PPi and adenosine levels and thereby address diseases caused by deficiencies in these molecules. Multiple press releases and business updates indicate that INZ-701 has been in clinical development for the treatment of ENPP1 Deficiency and ABCC6 Deficiency, with additional development efforts in calciphylaxis. Inozyme reported that INZ-701 reached late-stage clinical development in ENPP1 Deficiency, including a pivotal trial in pediatric patients, and that it was being evaluated in infants, children, and adults across several studies and expanded access programs.

Public statements from Inozyme emphasize that ENPP1 Deficiency is a serious, progressive, rare disease that affects blood vessels, soft tissues, and bones. Company and collaborator publications describe that individuals who present in utero or in infancy are often diagnosed with generalized arterial calcification of infancy (GACI Type 1), and that surviving children typically develop autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adolescents and adults may develop osteomalacia. The disease is associated with cardiovascular complications, rickets, bone pain, impaired mobility, hearing loss, and calcification in arteries and joints. Inozyme has highlighted that there were no approved therapies for ENPP1 Deficiency and that the condition requires coordinated, long-term management.

In addition, Inozyme has described ABCC6 Deficiency as a progressive rare disease that affects blood vessels and soft tissues, with infant presentations often classified as generalized arterial calcification of infancy (GACI Type 2) and later manifestations including pseudoxanthoma elasticum (PXE). Company communications note that ABCC6 Deficiency can lead to neurological and cardiovascular complications, abnormal mineralization in blood vessels and soft tissues, and visual and skin involvement. As with ENPP1 Deficiency, Inozyme has stated that there are no approved therapies for ABCC6 Deficiency.

Inozyme’s clinical and scientific communications indicate that the company has collaborated with disease experts and academic centers to characterize the natural history of ENPP1 Deficiency and related disorders. A JBMR Plus publication announced by Inozyme in April 2025 is described as the largest retrospective analysis of ENPP1 Deficiency to date, documenting the evolution of cardiovascular and musculoskeletal complications across the lifespan. The company has also reported interim clinical data from studies such as the ENERGY 1 and ENERGY 3 trials and from an expanded access program, highlighting observations on survival, arterial calcification, heart function, serum phosphate levels, rickets-related endpoints, and safety and immunogenicity of INZ-701 in affected infants, children, and adults.

In its public updates, Inozyme has repeatedly described itself as a clinical-stage organization, meaning it focused on research and development rather than on marketed products. The company’s strategy, as outlined in its press releases, involved prioritizing resources toward pivotal development of INZ-701 in ENPP1 Deficiency, while maintaining treatment access for certain ABCC6 Deficiency patients through extension and access programs and deferring some future trials. These communications also reference workforce reductions and portfolio prioritization measures intended to extend the company’s operational runway prior to its acquisition.

Following the acquisition by BioMarin, Inozyme’s common stock ceased trading on the Nasdaq Global Select Market, and Inozyme’s reporting obligations under Sections 13 and 15(d) of the Exchange Act were suspended, as documented in the Form 8-K filed on July 1, 2025, the Form 25 filed by Nasdaq on the same date, and the Form 15 filed on July 11, 2025. Inozyme continues as the surviving corporation in the merger and a wholly owned subsidiary of BioMarin, but INZY as a public trading symbol has been delisted and deregistered.

Business focus and therapeutic area

Across its public disclosures, Inozyme consistently frames its mission around rare, genetically defined diseases involving pathological mineralization and vascular and skeletal complications. The company’s expertise is described as centered on the PPi-Adenosine Pathway and ENPP1 biology. Its lead candidate, INZ-701, is positioned as an enzyme replacement therapy intended to restore or increase PPi and adenosine levels to address systemic disease manifestations. Development programs have focused on ENPP1 Deficiency and ABCC6 Deficiency, with additional interest in calciphylaxis and OPLL, all of which are linked in company materials to disruptions in mineralization and vascular biology.

Corporate status and listing history

Inozyme’s status as a former Nasdaq-listed issuer is documented in SEC filings. A Form 8-K dated July 1, 2025, states that BioMarin completed its acquisition of Inozyme pursuant to an Agreement and Plan of Merger dated May 16, 2025, and that, as a result of the merger, Inozyme became a wholly owned subsidiary of BioMarin. The same filing notes that Inozyme requested suspension of trading and delisting of its common stock from the Nasdaq Global Select Market and that Nasdaq would file a Form 25 to remove the listing and registration under Section 12(b) of the Exchange Act. The Form 25 filed on July 1, 2025, identifies Inozyme Pharma, Inc. as the issuer and Nasdaq Stock Market LLC as the exchange, and specifies that the common stock is being removed from listing and registration. The Form 15 filed on July 11, 2025, certifies termination of registration under Section 12(g) and suspension of reporting obligations under Sections 13 and 15(d), noting that there was one holder of record as of the certification date.

These documents collectively indicate that INZY is now a historical ticker symbol associated with a company that has been acquired and delisted, and that ongoing corporate activities related to Inozyme’s programs are conducted within BioMarin’s consolidated operations.

Key therapeutic programs mentioned in public disclosures

• INZ-701 in ENPP1 Deficiency: Company communications describe INZ-701 as an ENPP1 Fc fusion protein ERT in late-stage clinical development for ENPP1 Deficiency, including pivotal pediatric trials and studies in infants, children, and adults. Interim data releases have discussed safety, immunogenicity, biomarker changes such as PPi and serum phosphate, and clinical measures related to rickets and cardiovascular outcomes.
• INZ-701 in ABCC6 Deficiency: Inozyme has reported clinical development of INZ-701 in ABCC6 Deficiency, including adult studies and planning for a randomized controlled trial in pediatric patients, with an emphasis on major adverse clinical events and vascular and retinal pathology. Company updates also note regulatory interactions in the United States and Europe regarding trial design.
• Calciphylaxis and related indications: Company descriptions list calciphylaxis and OPLL among the conditions linked to disruptions in the PPi-Adenosine Pathway and to which INZ-701’s mechanism of action may be relevant, and refer to calciphylaxis as an area of clinical development interest.

INZY as a research and historical reference

Because Inozyme is now part of BioMarin and its stock has been delisted and deregistered, information associated with the INZY symbol primarily serves as a historical record of the company’s independent operations, therapeutic focus, and regulatory filings. Investors and researchers examining INZY-related materials can use these records to understand the evolution of INZ-701, the characterization of ENPP1 and ABCC6 Deficiencies, and the corporate steps leading to Inozyme’s acquisition and integration into BioMarin.